Recombinant antibody production employs Chinese hamster ovary (CHO) cells due to their robustness in expressing complex biologics. Improving these processes involves modifying various parameters, including cell line development, media formulation, and bioreactor environments. A key goal is to maximize antibody titer while lowering production expens